Embecta (EMBC) Projected to Post Quarterly Earnings on Tuesday

Embecta (NASDAQ:EMBC) is projected to release its Q4 2025 results before the market opens on Tuesday, November 25th. Analysts expect the company to announce earnings of $0.4550 per share and revenue of $265.6610 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 8:00 AM ET.

Embecta Trading Up 6.1%

Shares of EMBC opened at $14.57 on Friday. The firm has a market capitalization of $852.20 million, a price-to-earnings ratio of 10.19, a PEG ratio of 0.81 and a beta of 1.10. The firm’s 50-day moving average price is $14.09 and its 200-day moving average price is $12.46. Embecta has a 1-year low of $9.20 and a 1-year high of $21.48.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EMBC. Zacks Research downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Embecta in a research note on Friday, September 5th. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Embecta currently has an average rating of “Hold” and an average target price of $19.00.

Institutional Trading of Embecta

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. purchased a new stake in shares of Embecta during the third quarter valued at $192,000. Hancock Whitney Corp bought a new stake in Embecta during the 3rd quarter valued at about $237,000. Wexford Capital LP purchased a new stake in Embecta in the 3rd quarter valued at about $94,000. Sherbrooke Park Advisers LLC purchased a new stake in Embecta in the 3rd quarter valued at about $216,000. Finally, Mariner LLC bought a new position in Embecta in the 3rd quarter worth about $262,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.